Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Hematology Am Soc Hematol Educ Program. 2010;2010:82-9. doi: 10.1182/asheducation-2010.1.82.
Younger patients (defined as patients younger than 50-55 years of age) represent a small group of newly diagnosed patients with chronic lymphocytic leukemia, accounting only for 10% to 20% of newly diagnosed cases. However, once these patients become symptomatic and require treatment, their life expectancy is significantly reduced. Therapeutic approaches for younger patients should be directed at improving survival by achieving a complete remission and, where possible, eradicating minimal residual disease. Chemoimmunotherapy combinations carry the highest response rates and are commonly offered to younger patients. Additional strategies that should be considered for younger patients include early referral for stem-cell transplantation and clinical trials of consolidation therapy to eliminate minimal residual disease.
年轻患者（定义为年龄小于 50-55 岁的患者）占新发慢性淋巴细胞白血病患者的一小部分，仅占新发病例的 10%至 20%。然而，一旦这些患者出现症状并需要治疗，他们的预期寿命就会显著缩短。年轻患者的治疗方法应该旨在通过实现完全缓解和尽可能消除微小残留病来提高生存率。化疗免疫联合治疗组合具有最高的缓解率，通常适用于年轻患者。对于年轻患者，还应考虑其他策略，包括早期转介进行干细胞移植和微小残留病消除巩固治疗的临床试验。
